JP2013535487A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535487A5
JP2013535487A5 JP2013523278A JP2013523278A JP2013535487A5 JP 2013535487 A5 JP2013535487 A5 JP 2013535487A5 JP 2013523278 A JP2013523278 A JP 2013523278A JP 2013523278 A JP2013523278 A JP 2013523278A JP 2013535487 A5 JP2013535487 A5 JP 2013535487A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
acceptable salt
compound
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013523278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535487A (ja
JP6196154B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/046285 external-priority patent/WO2012018829A1/en
Publication of JP2013535487A publication Critical patent/JP2013535487A/ja
Publication of JP2013535487A5 publication Critical patent/JP2013535487A5/ja
Application granted granted Critical
Publication of JP6196154B2 publication Critical patent/JP6196154B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013523278A 2010-08-06 2011-08-02 C型肝炎ウイルス阻害剤の組み合わせ Expired - Fee Related JP6196154B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37139910P 2010-08-06 2010-08-06
US61/371,399 2010-08-06
PCT/US2011/046285 WO2012018829A1 (en) 2010-08-06 2011-08-02 Combinations of hepatitis c virus inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016072377A Division JP2016155844A (ja) 2010-08-06 2016-03-31 C型肝炎ウイルス阻害剤の組み合わせ

Publications (3)

Publication Number Publication Date
JP2013535487A JP2013535487A (ja) 2013-09-12
JP2013535487A5 true JP2013535487A5 (OSRAM) 2014-09-04
JP6196154B2 JP6196154B2 (ja) 2017-09-13

Family

ID=45559795

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013523278A Expired - Fee Related JP6196154B2 (ja) 2010-08-06 2011-08-02 C型肝炎ウイルス阻害剤の組み合わせ
JP2016072377A Withdrawn JP2016155844A (ja) 2010-08-06 2016-03-31 C型肝炎ウイルス阻害剤の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016072377A Withdrawn JP2016155844A (ja) 2010-08-06 2016-03-31 C型肝炎ウイルス阻害剤の組み合わせ

Country Status (14)

Country Link
US (3) US20120196794A1 (OSRAM)
EP (1) EP2600835B1 (OSRAM)
JP (2) JP6196154B2 (OSRAM)
KR (1) KR101846596B1 (OSRAM)
CN (2) CN105148275A (OSRAM)
AU (1) AU2011285890B2 (OSRAM)
BR (1) BR112013002922A2 (OSRAM)
CA (1) CA2807589C (OSRAM)
EA (1) EA022303B1 (OSRAM)
ES (1) ES2685174T3 (OSRAM)
IL (1) IL224369B (OSRAM)
MX (1) MX2013001170A (OSRAM)
SG (2) SG2014008346A (OSRAM)
WO (1) WO2012018829A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9243025B2 (en) * 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX360452B (es) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2435799T3 (es) * 2008-10-09 2013-12-23 Anadys Pharmaceuticals, Inc. Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors

Similar Documents

Publication Publication Date Title
JP2013535487A5 (OSRAM)
JP2015529652A5 (OSRAM)
JP2017008088A5 (OSRAM)
US20130072528A1 (en) Methods for Treating HCV
JP2016508134A5 (OSRAM)
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
JP2014527061A5 (OSRAM)
JP2011528713A5 (OSRAM)
US20130172240A1 (en) Methods for treating hcv
JP2014508804A5 (OSRAM)
EA201391337A1 (ru) Ингибиторы hsp90
TW201505633A (zh) 治療hcv的方法
WO2016134054A1 (en) Anti-viral compounds
JP2006511538A5 (OSRAM)
JP2014148552A5 (OSRAM)
US20140024613A1 (en) Methods for Treating HCV
JP2013532714A5 (OSRAM)
AR116922A1 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
RU2015101702A (ru) Фармацевтически активные соединения
JP2018521077A5 (OSRAM)
WO2017040896A1 (en) Anti-viral compounds
JP2009532494A5 (OSRAM)
JP2015526504A5 (OSRAM)
CA3070878A1 (en) Combination of midh1 inhibitors and dna hypomethylating agents (hma)
WO2016182935A1 (en) Anti-viral compounds